Federated Hermes
ITCI

Federated Hermes’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Federated Hermes’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-8,779
Closed -$457K – 2231
2023
Q3 		$457K Buy
+8,779
New +$511K ﹤0.01% 1368
2022
Q3 		– Sell
-19
Closed -$1K – 2262
2022
Q2 		$1K Buy
+19
New +$1.08K ﹤0.01% 2103
2020
Q4 		– Sell
-526
Closed -$13K – 2355
2020
Q3 		$13K Sell
526
-67,833
-99% -$1.55M ﹤0.01% 1943
2020
Q2 		$1.75M Buy
68,359
+24,906
+57% +$504K ﹤0.01% 1034
2020
Q1 		$668K Buy
43,453
+24,197
+126% +$526K ﹤0.01% 1289
2019
Q4 		$661K Buy
+19,256
New +$231K ﹤0.01% 1383
2018
Q3 		– Sell
-27
Closed -$1K – 2340
2018
Q2 		$1K Sell
27
-89,716
-100% -$1.82M ﹤0.01% 2165
2018
Q1 		$1.89M Sell
89,743
-66,842
-43% -$1.3M 0.01% 985
2017
Q4 		$2.27M Buy
156,585
+966
+0.6% +$14.9K 0.01% 888
2017
Q3 		$2.46M Sell
155,619
-27,416
-15% -$402K 0.01% 824
2017
Q2 		$2.27M Buy
183,035
+97,228
+113% +$1.13M 0.01% 853
2017
Q1 		$1.39M Buy
+85,807
New +$1.24M ﹤0.01% 1060

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Federated Hermes's ITCI Position: Q4 2023 in Review

Federated Hermes sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2023, closing a stake of 8,779 shares — an estimated $457K sold.

Federated Hermes first reported a position in ITCI in Q1 2017 and held it in 12 quarters. The position peaked at $2.46M in Q3 2017. 333 funds tracked by Wall St. Rank hold ITCI as of Q4 2023.

  • Federated Hermes reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2023 after selling out during the quarter.
  • Federated Hermes sold 8,779 Intra-Cellular Therapies Inc. shares in Q4 2023, an estimated $457K.
  • Federated Hermes first reported a position in Intra-Cellular Therapies Inc. in Q1 2017 and held it in 12 quarters.
  • Federated Hermes's Intra-Cellular Therapies Inc. position peaked at $2.46M in Q3 2017.
  • 333 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2023.

Based on Federated Hermes's 13F filing for Q4 2023, filed 31 Jan 2024.